Around The Web

Professor Wendy Rogers believes that overdiagnosis itself is an epidemic and that the roots of the problem lie in an insufficient naturalistic disease-theory. Overdiagnosis, she adds, “can be harmful for the patient and also cause waste of a lot of resources.”

In an interview with the New Scientist, former NIMH director Dr. Thomas Insel explained his decision to join Google and move to the private...

For the USC Center for Health Journalism, Martha Rosenberg points out the absurdity of allowing industry funded doctors to teach classes to practitioners about psychiatric drugs. "What if the written road test drivers take were sponsored by BP or Shell and had marketing messages interspersed?"

Oryx Cohen at TruthOut explains why the "Helping Families in Mental Health Crisis Act (HR 2646) - commonly known as the 'Murphy Bill' - appears to cater more closely to the desires of pharmaceutical companies than to the actual needs of people in psychological distress, perhaps because of Murphy's connections to key lobbyists." "If the Murphy Bill is passed, psychiatric hospitals and pharmaceutical companies will reap huge financial benefits as a result of increased hospitalization and forced treatment."

The German news agency DW features a video report on whether cannabidiol, an active substance derived from marijuana, can help relieve the symptoms of schizophrenia.

New York Times columnist, Nicholas Kristof, relates the story of Andrew Francesco, a boy who began taking Ritalin at age five and died from complications with Seroquel when he was fifteen. His father, a former pharmaceutical industry executive, reveals the industry’s greed in his memoir “Overmedicated and Undertreated.” Now the industry is pushing for a first-amendment right to market its drugs for off-label uses.

Two companies have committed to FDA review for video games that they claim can be used to treat “ADHD,” but many scientists remain skeptical. “At the annual meeting of the American Academy of Child & Adolescent Psychiatry on Wednesday, Akili Interactive Labs presented data from a pilot study of its video game, Project: EVO, that showed some positive results in children with attention-deficit hyperactivity disorder (ADHD).”

Mad Studies is emerging as a new academic discipline in Canada and proponents are challenging popular conceptions of “madness” and the medicalization human experiences.

As the UK debates whether to ban smoking inside and outside of mental health hospitals, the BMJ has solicited opinion pieces on the debate for an upcoming issue. However, psychiatric survivors have come forward alleging that the BMJ refused to print their pieces unless they removed descriptions of forced treatment and coercive care.

Legislation is being advanced that would speed up the FDA’s approval process for new drugs and medical devices, according to a report by the Pacific Standard. Pharmaceutical and medical device companies have been lobbying heavily to reduce regulations and are winning over bipartisan support by attaching these measures to increased mental health funding.

The Boston Herald reports on mental health care reform bills moving through both houses of Congress. Lawmakers warn, however, “that some aspects of the legislation could create greater barriers to access mental health care for some.”

At Alternet, Jay Syrmopoulos of The Free Thought Project discusses new research on the use of medical marijuana as a treatment for ADHD within the context of the ongoing debate over the validity of the ADHD diagnosis.

Nature magazine reports on recent discoveries by neuroscientists that microbes that live in the intestinal track may have an influence on brain development and behavior. “Researchers have drawn links between gastrointestinal pathology and psychiatric neurological conditions such as anxiety, depression, autism, schizophrenia and neurodegenerative disorders—but they are just links.”

Dr. Thomas Insel worked as the director of the NIMH for thirteen years, and now he is moving on to Google where he hopes to help develop technology to monitor our mental health.

A small study of 30 participants in Germany claims that cannabis can be used to treat “ADHD” because it increases the availability of dopamine. "This then has the same effect but is a different mechanism of action than stimulants like Ritalin and dexedrine amphetamine, which act by binding to the dopamine and interfering with the metabolic breakdown of dopamine." According to the report, 22 of the 30 participants opted to discontinue their prescriptions in favor of medical marijuana.

The Guardian reports growing concerns from the Buddhist Society conference: “Jon Kabat-Zinn, who created the Center for Mindfulness in Medicine at the University of Massachusetts medical school, warned last week that some people feared a ‘sort of superficial ‘McMindfulness’ is taking over, which ignores the ethical foundations of the meditative practices and traditions from which mindfulness has emerged, and divorces it from its profoundly transformative potential.’”

Robert Neugeboren, who “spent most of his adult life in institutions, often subject to isolation, physical punishment and numbing medication,” was “a celebrity of sorts in the world of the mentally ill: a survivor of the horrors of mistreatment, a case history for those who point to the positive effects of kindness and talk therapy, and, perhaps most of all, the embodiment of the bottomless mystery of the human mind.”

The UK Independent reports that Ireland is moving toward a policy of decriminalizing small amount of drugs like heroin, cocaine, and cannabis in what amounts to a “radical cultural shift.” While it would remain a crime to profit from the sale of these substances, users will have specially designated areas for safe use. The chief of Ireland’s National Drugs Strategy told the paper: “I am firmly of the view that there needs to be a cultural shift in how we regard substance misuse if we are to break this cycle and make a serious attempt to tackle drug and alcohol addiction.”

A Quebec City pharmacy claims it accidentally mixed antipsychotic drug pills into a candy basket that was distributed to trick-or-treating children.

Marcia Angell in the New York Review of Books writes about the inherent conflict in clinical trials between “the search for scientific answers," on one hand, and “the rights and welfare of human subjects,” on the other.

In an op-ed for the Guardian, cardiologist Aseem Malhotra writes: “Corporate greed and systematic political failure have brought healthcare to its knees. There are too many misinformed doctors and misinformed patients. It’s time for greater transparency and stronger accountability, so that doctors and nurses can provide the best quality care for the most important person in the consultation room – the patient.”

NPR interviews Dr. Lance Dodes, author of The Sober Truth: Debunking the Bad Science Behind Twelve-Step Programs and the Rehab Industry. Despite the fact...

Google has hired the former director of the National Institute of Mental Health (NIMH), Thomas Insel, with plans to create “a wearable sensor to measure mood, cognition and anxiety.” Gizmodo points out the problems with this idea:“One can easily imagine a message popping up on some poor desk jockey’s monitor: ‘You’re not in the right mood today. Please take a day of unpaid leave.’ Or, worse: ‘We’ve detected signs of mental instability, based on how you’ve been talking and sleeping. Please report to a doctor immediately.’”

The science magazine RUBIN provides an update on patients’ rights to refuse treatment in Germany's psychiatric wards. “In psychiatric wards in Germany, patients used to be medicated indiscriminately against their will if doctors considered it necessary. It was only after a Federal Constitution Court ruling a few years ago that patient autonomy has been strengthened.”

In a Science Update, the National Institute of Mental Health (NIMH) reports that Medicaid services is already taking steps to implement “coordinated specialty care” (CSC) in response to the RAISE study released last week. “The RAISE initiative has shown that coordinated specialty care for first episode psychosis is better than the standard care offered in community clinics. However, covering the cost of coordinated specialty care can be challenging. When Medicaid agrees to pay for effective treatment programs, patients in need benefit.”